Answers are grounded in this paper and cite their sources.
Engineered M1 macrophage-derived EVs and MoS2 enhance tumor-targeted therapy, suggesting better outcomes for bladder cancer.
M1 macrophage-derived EVs engineered with MoS 2 enable tumor-targeted photothermal-immunotherapy, suppressing bladder cancer via potential CD8 + T-cell activation, PD-L1 reduction, and ROS generation under NIR irradiation. Created in BioRender. Chuang, A. (2025) https://BioRender.com/ct5w2pa.
No takes yet. Share an insight, caveat, or question.
Chuang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: